Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Halberd Corp HALB

Halberd Corporation is a holding company. The Company is engaged in the acquisition vehicle for established businesses. It is also developing treatments for neurodegenerative diseases, such as post-traumatic stress disorder/chronic traumatic encephalopathy (PTSD/ CTE), Alzheimer’s disease and Parkinson’s disease. It has two issued patents and four provisional patent applications related to the extracorporeal treatment of blood-borne diseases and cerebrospinal fluid related diseases, with particular focus on the treatment and rapid detection of Covid-19 and other viruses. Its Sequential Dialysis Technique is a methodology that physically removes the pathophysiologic basis of the disease, eliminating it without side effects. The Company’s wholly owned subsidiary is Alaric Corporation.


OTCPK:HALB - Post by User

Halberd Corp
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(9)
•••
Post by averagepennieson Oct 10, 2023 8:26am
62 Views
Post# 35676645

Hartman, CEO, and Dr. Felder, CTO of Halberd Corp, Featured

Hartman, CEO, and Dr. Felder, CTO of Halberd Corp, Featured

JACKSON CENTER, PA / ACCESSWIRE / October 10, 2023 / Halberd Corporation (OTC PINK:HALB) Chairman, President and CEO William A. Hartman and Chief Technology Officer, Dr Mitchell S. Felder were recently interviewed on "The Street Reports Podcast" to update the public on several of the company's important projects:

  • The significant results to-date of Halberd's proprietary nasal spray testing at Mississippi State University to mitigate the adverse effects of Traumatic Brain Injury (TBI)
  • Progress in securing a partnership with Athena GTX
  • Continuing studies at Youngstown State University
  • Sponsored Research project at Stanford University Medical School examining TBI treatments and Multiple Sclerosis.

Listen here: https://thestreetreports.com/halbs-ceo-william-hartman-and-cto-dr-mitchell-felder-discuss-msu-ysu-testing-athena-gtx-partnership-updates-etc-on-the-street-reports-podcast-listen-now/

 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities